ALFA Finder| Net Profit: guided vs achieved | 800.00% achieved Guided 700.00%–750.00%, 6.7% above the top of the range; confirmed by management |
|---|---|
| Management target | Revenue 15.0% FY28 |
| Revenue growth | ₹1019.4 Cr revenue, YoY decline due to lower Revlimid sales. |
|---|---|
| Margins | EBITDA margin at 30.4%, deemed sustainable by management. |
| Demand visibility | Strong traction in Brazil/Middle East; US remains a high-risk volume game. |
| Management confidence | Confident, shifting focus from 'lumpy' exclusivities to stable diversified base earnings. |
Growth
Strong international formulation growth led by a 66% jump in Brazil and steady base US business despite pricing pressure.
Outlook
Management raised PAT guidance to ₹775-800 Cr for FY27; FY28 target is 10-15% top-line growth.
Risks
Substantial price erosion in Pomalidomide due to multiple generic entrants and a 4-6 month delay in the agrochemical demerger.
Earnings Call Transcript filed with NSE, NSE: NATCOPHARM. Summary written with AI assistance from the document.
Natco Pharma Ltd: key numbers
- Share price
- ₹810.45
- Market cap
- ₹15,898 Cr
- Revenue (annual)
- ₹4,078 Cr
- Net profit (annual)
- ₹1,418 Cr
- P/E (TTM)
- 19.2×Sector 43.7×
- Promoter holding
- 46.22%-3.20% QoQ
- FII holding
- 15.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Natco Pharma Ltd
All →Natco Pharma Investor Presentation: Key Takeaways
Q2 FY27 consolidated revenue ₹10,194Mn (−30% YoY, +28% QoQ), EBITDA margin 30.4%, PAT ₹2,026Mn. Pipeline and Adcock Ingram stake increase highlighted.
Natco Pharma Dividend
Natco Pharma declared 2nd interim dividend of Rs.1.25 per share for FY26-27. Record date is November 19, 2026; payment begins November 27.
Natco Pharma Q2 FY27 Results: Net Profit ₹202.6 Cr, Down 60.9% YoY
Natco Pharma Ltd reported revenue from operations of ₹967.3 Cr (-29.0% YoY) and net profit of ₹202.6 Cr (-60.9% YoY) for Q2 FY27.
- Key figure
- Net profit ₹202.6 Cr · -60.9% YoY
Natco Pharma Share Pledge
Natco Pharma promoter V.C. Nannapaneni pledged 8,50,000 equity shares to Bajaj Financial Securities Limited. The pledge supports the promoter's subscription to the company's Rights Issue.
Natco Pharma Other Announcement
Natco Pharma filed its shareholding pattern with a reporting date of 23 October 2026. Promoter and promoter group hold about 46% of total equity.
Natco Pharma Capital Structure Change
Natco Pharma allotted 5,86,666 equity shares to promoter Venkaiah Chowdary Nannapaneni via its rights issue, valued at ~₹44 Crore. This lifts his stake to 14.60%.
- Value
- ₹44.00 Cr